Zhejiang DTRM Biopharma Report issue

For profit Phase 1 Phase 2
Founded: Hangzhou China (2011)

Organization Overview

First Clinical Trial
2016
NCT02900716
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Zhejiang DTRM Biopharma

Active Ingredients

Drugs in Phase 2 Trials (1)

dtrm-555 (2 trials)

Drugs in Phase 1 Trials (2)

dtrm-505 (1 trial)

dtrmwxhs-12 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3